Monday, March 15, 8:00 AM - 9:30 AM
In an address to the media, ACC.10 program chairs highlighted some of these late-breaking clinical trials as potential game-changers. In particular, the RACE II trial, depending on the results, could inform how to best control the blood pressure of patients with atrial fibrillation (AF).
Over the last few years, there have been scattered studies evaluating the impact of remote monitoring of patients with implantable devices. This session will contribute to the growing evidence. The study looked that automatic clinical notification via remote monitoring. If past studies are any indication, we can assume that the remote monitoring made for more efficient patient care and better use of physician time. But we’ll have to wait for the results to know for sure.
The abstracts being presented are:
- Cryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial Fibrillation: First Results of the North American Arctic Front Stop-AF Clinical Trial (Mayo Clinic/St. Mary’s Hospital, Rochester, Minn.)
- Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure. The RACE II Study (Medical Center Groningen, The Netherlands)
- The Impact of Remote Monitoring with Automatic Clinician Notifications on the Clinical Care of ICD and CRT-D Patients (St. Thomas Research Institute, Nashville)
- A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients with Atrial Fibrillation (Lankenau Institute for Medical Research, Wynnewood, Pa.)
- Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: First Results of the CABANA Pilot Study (Mayo Clinic, Rochester, Minn.)
Location: Murphy Ballroom
Byron K. Lee, MD, San Francisco
Kevin M. Monahan, MD, Boston
A. John Camm, MD, London
John M. Miller, MD, Indianapolis
Lars Wallentin, MD, Uppsala, Sweden